Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is an immuno-pharma company with a potentially lucrative market opportunity for its flagship drugs Ampligen and Alferon N Injection in treating various cancers and viral diseases. With ongoing clinical trials and collaborations with larger companies like AstraZeneca, the company has strong growth prospects and potential catalysts for its stock. The recent focus on pancreatic cancer treatment and positive clinical data also add to the potential for high rewards, although there are still risks such as balance sheet and liquidity concerns, regulatory approvals, and competition to consider.

Bears say

AIM ImmunoTech is currently focusing on developing their flagship product, Ampligen, for the treatment of late-stage pancreatic cancer, which has shown success in safety and efficacy in clinical trials and has a large market with high mortality rates. The company expects to announce interim results from its various clinical trials in 2026/27, and with $6 million in cash and the recent raise of $6 million in stock, we believe they have enough cash to support their operations until late-2027. The company is located in Ocala, FL, and with upcoming clinical data from their trials, there is potential for positive catalysts for their stock.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.